Clinical trials: Gefitinib
Carcinoma, Non-Small-Cell Lung
Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV
Patients presenting a deterioration of the general state (performance status [PS] 2-3), constitute a population which needs an adapted treatment.
- Trial name
- NCT00198393
- Testing
- Gefitinib, gemcitabine, Docetaxel
- Where
- 2 sites in France
- Volunteers
- 126 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Head and Neck Cancer, Carcinoma, Squamous Cell
Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck
To determine safety profile of the epidermal growth factor receptor (EGFR) antagonist, ZD1839 in combination with cisplatin and radiation therapy in patients with local-regional recurrent squamous cell cancer of the head and…
- Trial name
- NCT00185835
- Testing
- ZD-1839, Cisplatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Non-small Cell Lung Cancer
Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Pemetrexed was known to be effective to pulmonary adenocarcinoma and gefitinib was known to be more effective to non-small cell lung cancer (NSCLC) patients with clinical characteristics such as adenocarcinoma, never smoker and…
- Trial name
- NCT01066195
- Testing
- iressa, alimta
- Where
- South Korea
- Volunteers
- 129 people
- Sponsor
- Samsung Medical Center
Non-Small-Cell Lung Cancer
UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer
Iressa [epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI)] has been reported to activity against Non-small-cell Lung Cancer (NSCLC) failed previous chemotherapy.
- Trial name
- NCT01037998
- Testing
- UFUR and Iressa
- Where
- Taiwan
- Volunteers
- 115 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Metastatic Pancreatic Carcinoma
Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer
The purpose of this study is to find out what activity the combination of docetaxel and Iressa have against metastatic pancreatic cancer.
- Trial name
- NCT00137761
- Testing
- ZD 1839, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Hormone therapy using tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00080743
- Testing
- gefitinib, tamoxifen citrate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Neoplasms, Squamous Cell
IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
The primary purpose of this study is to assess the effectiveness of ZD1839 250 mg and 500 mg when given either concomitantly or as maintenance to a standard therapy of radiotherapy (X-rays) plus chemotherapy (cisplatin) in terms…
- Trial name
- NCT00229723
- Testing
- gefitinib (Iressa), cisplatin, radiotherapy
- Where
- 25 sites in United States, Belgium and 6 more
- Volunteers
- 224 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Phase II Iressa & Carbo/Gem in NSCLC
The primary objective is to demonstrate in chemotherapy naïve patients with advanced (Stage IIIB or IV) NSCLC and ECOG PS 2 non-inferiority in progression free survival (PFS) for ZD1839 compared to gemcitabine/carboplatin.
- Trial name
- NCT00264498
- Testing
- Gefitinib, Gemcitabine, Carboplatin
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- AstraZeneca
Brain Neoplasms, Non Small Cell Lung Cancer
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC
- Trial name
- NCT00234442
- Testing
- Iressa (Gefitinib)
- Where
- 4 sites in Italy
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Advanced Tumor
Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
Phase I AZD2171 in combination with ZD1839 study recruiting patients with advanced cancer
- Trial name
- NCT00502060
- Testing
- AZD2171, ZD1839
- Where
- 3 sites in Netherlands
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Tumors
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
This study will determine the safety profile and maximum tolerated dose (MTD) of orally administered gefitinib on a weekly and twice weekly schedule.
- Trial name
- AGUS (NCT00127829)
- Testing
- Gefitinib
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- AstraZeneca
Breast Cancer
A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer
The progression free survival and efficacy of 250 mg ZD1839 in combination with a fixed dose of fulvestrant 250 mg im once a month will be evaluated in female patients with histologically-confirmed advanced or metastatic, ER…
- Trial name
- NCT00234403
- Testing
- gefitinib and fulvestrant
- Where
- 7 sites in Spain
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer
The primary objective of the trial is to identify the dose of gemcitabine given as a 2-hour intravenous (iv) infusion that can be administered in combination with ZD1839 250 mg once daily and a standard course (45 Grays [Gy]) of…
- Trial name
- NCT00234416
- Testing
- Gefitinib, Gemcitabine
- Where
- 2 sites in Spain
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC
Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer
To assess safety, efficacy and explorative objectives of gefitinib in combination with chemoradiation in resectable gastric cancer
- Trial name
- NCT00237900
- Testing
- Gefitinib, 5-fluorouracil, leucovorin and radiotherapy
- Where
- Finland
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Non-Metastatic Prostate Cancer
Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer
To estimate the safety and tolerability of 250 mg ZD1839 given concurrently with 3D-CRT in patients with non-metastatic prostate cancer
- Trial name
- NCT00239291
- Testing
- Gefitinib, radiotherapy
- Where
- Finland
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Prostate Cancer
Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy
To evaluate activity of gefitinib in subjects with relapsed prostate cancer by estimating PSA response rate at study closure
- Trial name
- NCT00241475
- Testing
- Gefitinib
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Cancer of Head and Neck
IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma
· To evaluate the disease free survival rate at 2 years of patients with advanced head and neck carcinoma treated with ZD1839 250 mg administered once daily in combination with cisplatin and a standard course of radiotherapy.
- Trial name
- NCT00242749
- Testing
- Gefitinib, Cisplatin and Radiotherapy
- Where
- 4 sites in Spain
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Colorectal Cancer
IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure
The primary objective of the Phase I part of the study is to determine the recommended dose of capecitabine to be administered in combination with ZD1839 250 mg orally once daily in subjects with advanced or metastatic colorectal…
- Trial name
- NCT00242788
- Testing
- Gefitinib and capecitabine
- Where
- 6 sites in Spain
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
NSCLC
Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study
This study is being carried out to see if adding ZD1839 to other standard supportive care is more effective than standard supportive care alone for the treatment of patients with NSCLC whose disease has recurred after previous…
- Trial name
- NCT00242801
- Testing
- Gefitinib
- Where
- 211 sites in Argentina, Australia and 30 more
- Volunteers
- 1,692 people
- Sponsor
- AstraZeneca
Breast Cancer
ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer
This is a multicentre, randomised (2:1), double blind, non-comparative phase II trial of ZD1839 and placebo in combination with chemotherapy in patients with metastatic breast cancer.
- Trial name
- NCT00247481
- Testing
- Gefitinib, Docetaxel
- Where
- 5 sites in France
- Volunteers
- 77 people
- Sponsor
- AstraZeneca